Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2013 (2013), Article ID 451206, 3 pages
http://dx.doi.org/10.1155/2013/451206
Case Report

A Rare Neurological Complication of Ranolazine

1VA Western New York Healthcare System, Division of Critical Care and Pain Medicine, Department of Anesthesiology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14215, USA
2University of Iowa, Mason City Cardiology, Mason City, IA 50401, USA
3Director of Mercy North-Iowa Neurology and Sleep Laboratory, University of Iowa, Mason City Neurology, Mason City, IA 50401, USA

Received 24 May 2013; Accepted 19 June 2013

Academic Editors: T. K. Banerjee, P. Berlit, J. L. González-Gutiérrez, R. Koide, and Y. Wakabayashi

Copyright © 2013 Jahan Porhomayon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. R. Chaitman, “When should ranolazine be considered for the treatment of chronic angina?: commentary,” Nature Clinical Practice Cardiovascular Medicine, vol. 3, no. 11, pp. 590–591, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Bonadei, E. Vizzardi, F. Quinzani et al., “Effects of ranolazine on cardiovascular system,” Recent Patents on Cardiovascular Drug Discovery, vol. 6, no. 3, pp. 215–221, 2011. View at Google Scholar · View at Scopus
  3. G. Schram, L. Zhang, K. Derakhchan, J. R. Ehrlich, L. Belardinelli, and S. Nattel, “Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects,” British Journal of Pharmacology, vol. 142, no. 8, pp. 1300–1308, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. W. C. Stanley, “Partial fatty acid oxidation inhibitors for stable angina,” Expert Opinion on Investigational Drugs, vol. 11, no. 5, pp. 615–629, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Clarke, K. M. Wyatt, and J. G. McCormack, “Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism,” Journal of Molecular and Cellular Cardiology, vol. 28, no. 2, pp. 341–350, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. J. G. McCormack, W. C. Stanley, and A. A. Wolff, “Ranolazine: a novel metabolic modulator for the treatment of angina,” General Pharmacology, vol. 30, no. 5, pp. 639–645, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. B. R. Chaitman, “Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions,” Circulation, vol. 113, no. 20, pp. 2462–2472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Antzelevitch, L. Belardinelli, A. C. Zygmunt et al., “Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties,” Circulation, vol. 110, no. 8, pp. 904–910, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Sicouri, J. Blazek, L. Belardinelli, and C. Antzelevitch, “Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine,” Circulation, vol. 5, no. 2, pp. 371–379, 2012. View at Google Scholar
  10. M. Jerling, B.-L. Huan, K. Leung, N. Chu, H. Abdallah, and Z. Hussein, “Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects,” Journal of Clinical Pharmacology, vol. 45, no. 4, pp. 422–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Abdallah and M. Jerling, “Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets,” Journal of Clinical Pharmacology, vol. 45, no. 7, pp. 802–809, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Jerling, “Clinical pharmacokinetics of ranolazine,” Clinical Pharmacokinetics, vol. 45, no. 5, pp. 469–491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Jerling and H. Abdallah, “Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine,” Clinical Pharmacology and Therapeutics, vol. 78, no. 3, pp. 288–297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Jones, “Ranolazine roche bioscience,” IDrugs, vol. 2, no. 12, pp. 1353–1362, 1999. View at Google Scholar · View at Scopus
  15. N. K. Wenger, B. Chaitman, and G. W. Vetrovec, “Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials,” American Journal of Cardiology, vol. 99, no. 1, pp. 11–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Koren, M. R. Crager, and M. Sweeney, “Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE),” Journal of the American College of Cardiology, vol. 49, no. 10, pp. 1027–1034, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Rajamani, J. C. Shryock, and L. Belardinelli, “Block of tetrodotoxin-sensitive, NaV1.7 and tetrodotoxin-resistant, NaV1.8, Na+ channels by ranolazine,” Channels, vol. 2, no. 6, pp. 449–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. B. W. Jarecki, A. D. Piekarz, J. O. Jackson II, and T. R. Cummins, “Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 369–378, 2010. View at Publisher · View at Google Scholar · View at Scopus